Alnylam Pharmaceuticals, Inc. $ALNY Shares Bought by Danske Bank A S

Key Points

• Q1 beat: Alnylam reported Q1 EPS of $1.99 versus $0.90 expected and revenue of $1.17B (up 96% y/y), with Amvuttra sales up ~187% driving the gain.
• Institutional backing and analyst view: Danske Bank raised its stake 17.1% to 67,201 shares (≈$26.7M), institutional investors own 92.97% of the stock, and analysts have a consensus "Moderate Buy" with a $471.96 price target.
• Insider selling: Insiders sold 38,656 shares (~$12.37M) in the last 90 days, including EVP Jeffrey Poulton and Melissa McLaughlin, with some sales executed under a Rule 10b5‑1 plan to cover tax withholding.

Danske Bank A S raised its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 17.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 67,201 shares of the biopharmaceutical company's stock after acquiring an additional 9,794 shares during the period. Danske Bank A S owned 0.05% of Alnylam Pharmaceuticals worth $26,722,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Root Financial Partners LLC acquired a new position in Alnylam Pharmaceuticals in the third quarter valued at approximately $25,000. Salomon & Ludwin LLC acquired a new position in Alnylam Pharmaceuticals in the third quarter valued at approximately $27,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Alnylam Pharmaceuticals during the third quarter worth approximately $29,000. Ameriflex Group Inc. acquired a new position in shares of Alnylam Pharmaceuticals during the third quarter worth approximately $32,000. Finally, ORG Partners LLC boosted its position in shares of Alnylam Pharmaceuticals by 70.2% during the third quarter. ORG Partners LLC now owns 80 shares of the biopharmaceutical company's stock worth $36,000 after buying an additional 33 shares during the period. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, EVP Jeffrey V. Poulton sold 2,206 shares of the business's stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $327.65, for a total transaction of $722,795.90. Following the sale, the executive vice president owned 64,273 shares of the company's stock, valued at $21,059,048.45. The trade was a 3.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Melissa Mclaughlin sold 2,286 shares of the business's stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $330.42, for a total value of $755,340.12. Following the sale, the insider directly owned 9,443 shares in the company, valued at approximately $3,120,156.06. The trade was a 19.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 38,656 shares of company stock valued at $12,370,696 over the last 90 days. Corporate insiders own 0.86% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on ALNY shares. Barclays started coverage on Alnylam Pharmaceuticals in a research report on Wednesday, January 28th. They set an "overweight" rating and a $527.00 price objective for the company. Oppenheimer started coverage on Alnylam Pharmaceuticals in a research report on Wednesday, January 7th. They set an "outperform" rating and a $500.00 price objective for the company. HC Wainwright reiterated a "buy" rating and set a $510.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Wednesday, March 25th. Raymond James Financial reiterated an "outperform" rating and set a $472.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Monday, January 12th. Finally, Wells Fargo & Company boosted their price objective on Alnylam Pharmaceuticals from $376.00 to $377.00 and gave the stock an "equal weight" rating in a research report on Friday. One investment analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, five have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $471.96.

Trending Headlines about Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Q1 beat driven by Amvuttra — Alnylam reported Q1 EPS of $1.99 and revenue of $1.17B, topping estimates; Amvuttra sales surged ~187% and helped drive 96% year‑over‑year revenue growth. Read More.
• Positive Sentiment: Brokerage support — Several brokerages continue to rate ALNY favorably (consensus around “moderate buy” and H.C. Wainwright remains a buy), which supports upside sentiment over the medium term. Read More.
• Neutral Sentiment: Mixed analyst target moves — Wells Fargo nudged its target slightly higher but kept an “equal weight” stance; RBC trimmed its target marginally but maintains an “outperform” view (still implying sizeable upside). These are tweaks rather than directional shifts. Read More. Read More.
• Neutral Sentiment: Investor materials and commentary available — Full earnings slide deck and call transcript were published (useful for modeling product-level trends and guidance; contributes to re‑rating discussions). Read More.
• Negative Sentiment: Risks and product headwinds — The quarter showed declines in collaborator revenue and Onpattro sales that offset some gains; an outside review highlighted a new regulatory risk and warned the stock could carry a higher risk of significant losses, which likely pressured sentiment. Read More.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ:ALNY opened at $296.11 on Friday. Alnylam Pharmaceuticals, Inc. has a 12 month low of $245.96 and a 12 month high of $495.55. The stock has a market cap of $39.51 billion, a price-to-earnings ratio of 80.90 and a beta of 0.31. The stock's 50 day moving average price is $320.11 and its 200 day moving average price is $376.83. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.76 and a quick ratio of 2.71.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 EPS for the quarter, topping the consensus estimate of $0.90 by $1.09. Alnylam Pharmaceuticals had a return on equity of 118.63% and a net margin of 11.72%.The firm had revenue of $1.17 billion for the quarter, compared to analysts' expectations of $1.12 billion. During the same quarter in the previous year, the company earned ($0.44) earnings per share. The firm's quarterly revenue was up 96.4% compared to the same quarter last year. Equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 6.78 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc NASDAQ: ALNY is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.